Serum albumin may independently predict outcomes in patients undergoing surgical ablation of head and neck cancer

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-09-22 21:30 GMT   |   Update On 2023-09-23 10:29 GMT

Serum albumin may independently predict outcomes in patients undergoing surgical ablation of head and neck cancer suggests a new study published in the Journal of Oral and Maxillofacial Surgery.Patients with head and neck cancer are at increased risk of malnutrition due to tumor burden and surgical morbidity.The purpose of this study was to evaluate the association between preoperative...

Login or Register to read the full article

Serum albumin may independently predict outcomes in patients undergoing surgical ablation of head and neck cancer suggests a new study published in the Journal of Oral and Maxillofacial Surgery.

Patients with head and neck cancer are at increased risk of malnutrition due to tumor burden and surgical morbidity.

The purpose of this study was to evaluate the association between preoperative serum albumin and 30-day adverse outcomes in patients undergoing head and neck cancer surgery.

This was a retrospective cohort study using the American College of Surgeons National Surgical Quality Improvement Program database. Patients undergoing an ablative head and neck cancer procedure were included. Patients who had an unclear tumor location based on coding or missing outcome data were excluded. The primary predictor variable was preoperative albumin categorized as low (<3.4 g/dL), intermediate (3.4 to 3.9 g/dL), or high (>3.9 g/dL). The primary outcome variable was intensive care unit (ICU)-level complications scored using the Clavien-Dindo classification system. This is a tool used to grade surgical complications, with grade IV and V complications defined as requiring ICU-level care.

Covariates were demographic (age, sex, body mass index), medical (smoking, functional status, weight loss), and perioperative (concurrent procedures, tumor location, reconstructive modality). Descriptive, bivariate, and multiple logistic regression with bootstrap resampling statistics were used to evaluate the association between albumin and adverse outcomes. A significance level of P ≤ .05 was significant.

Results

A total of 4,491 subjects met inclusion criteria and had a documented albumin. There were 435 subjects with low albumin levels, 1,305 with intermediate levels, and 2,751 with high levels. In bivariate analysis, low albumin levels were associated with an increased risk of ICU-level complications, any complication, extended length of stay, and adverse discharge disposition (all P ≤ .001), while high levels were protective (all P ≤ .001). In bootstrapped multivariate analysis using intermediate albumin as the reference group and adjusting for demographics, tumor location, and reconstructive modality among others, low albumin levels were an independent predictor of ICU-level complications (P = .008, odds ratio, 1.64; 95% confidence interval, 1.14 to 2.40), while high levels were protective (P = .014, odds ratio, 0.689; 95% confidence interval, 0.521 to 0.923).

Preoperative serum albumin was an independent predictor of adverse outcomes following ablative head and neck cancer procedures.

Reference:

Cameron C. Lee, Tim T. Wang, Joshua E. Lubek, Donita Dyalram, :August 23, 2023DOI:https://doi.org/10.1016/j.joms.2023.08.162. Is Preoperative Serum Albumin Predictive of Adverse Outcomes in Head and Neck Cancer Surgery?

Keywords:

Cameron C. Lee, Tim T. Wang, Joshua E. Lubek, Donita Dyalram, Serum albumin, independently, predict, outcomes, patients, undergoing, surgical, ablation, head, neck cancer , Journal of Oral and Maxillofacial Surgery

Tags:    
Article Source : Journal of Oral and Maxillofacial Surgery

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News